Solid Tumours clinical trials

Explore recruiting solid tumours clinical trials.

Recruiting solid tumours studies right now

Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record

Also recruiting in Europe

Solid Tumours trials registered in the EU Clinical Trials Information System (CTIS). These are outside the "near me" matcher above - open a study for full details.

A Phase 1 study to look at RP-6306 in combination with FOLFIRI as a treatment for Advanced Solid Tumours

Spain

Human Pharmacology (Phase I)- First administration to humans EU CTIS Study details

A Phase I/IIa Open-label Dose Escalation and Expansion Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Efficacy of AZD7789, an anti-PD-1 and anti-TIM-3 Bispecific Antibody, in Participants with Advanced or Metastatic Solid Tumors

Spain, Netherlands, France

Phase I and Phase II (Integrated)- First administration to humans EU CTIS Study details

A clinical trial to look at how ZN-A-1041 alone or ZN-A-1041 plus some approved drugs works to reduce tumor size and how safe these drugs are at different doses.

France, Spain, Italy

Human Pharmacology (Phase I)- First administration to humans EU CTIS Study details

A Phase I/II Open-label Dose Escalation and Dose Expansion Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Efficacy of AZD4360 in Adult Participants with Advanced Solid Tumours

Germany

Phase I and Phase II (Integrated)- First administration to humans EU CTIS Study details

A 2-part phase 1/2 open-label trial evaluating the safety, tolerability, pharmacokinetics, pharmacodynamics, and efficacy of ODM-212 in combination with anti-cancer therapy in participants with advanced solid tumours

Finland, Denmark, Spain, France

Phase I and Phase II (Integrated)- Other EU CTIS Study details

Phase 1b/2 study of liposomal annamycin (l-annamycin) in patients with previously treated metastatic soft-tissue sarcomas (ANNA-SARC)

Poland

Phase I and Phase II (Integrated)- Other EU CTIS Study details

Solid Tumours trials by city

Solid Tumours in Toronto Solid Tumours in Vancouver Solid Tumours in Montreal Solid Tumours in Calgary Solid Tumours in Edmonton Solid Tumours in Ottawa Solid Tumours in Winnipeg Solid Tumours in Quebec City Solid Tumours in Hamilton Solid Tumours in Kitchener Solid Tumours in London Solid Tumours in Halifax Solid Tumours in New York Solid Tumours in Los Angeles Solid Tumours in Chicago Solid Tumours in Houston

Other conditions

Obesity Type 2 diabetes Type 1 diabetes Prediabetes Weight loss Metabolic syndrome High cholesterol High triglycerides High blood pressure PCOS Hypothyroidism Thyroid disease Gout Fatty liver disease (NAFLD/NASH) Heart failure Coronary artery disease Atrial fibrillation Stroke Stroke recovery Peripheral artery disease Pulmonary hypertension Deep vein thrombosis Chronic kidney disease Diabetic kidney disease